AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
methenamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3344 | 100-97-0 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
An anti-infective agent most commonly used in the treatment of urinary tract infections. Its anti-infective action derives from the slow release of formaldehyde by hydrolysis at acidic pH. (From Martindale, The Extra Pharmacopoeia, 30th ed, p173)
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 2 | g | O |
| 3 | g | O |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,MAP2K6,MAP3K21,MAP3K7,MAPK7,MET,NTRK2,PDK2,PDK4,PIK3CD,PIM2,PRKCD,PRKDC,SIK2,SIK3,STK33,TEK,TGFBR1,TTK,ULK1 | 37 | |||
| kinase-selectivity-class | AAK1,AXL,CAMK2D,CDK4,CDK7,CSK,EPHB4,FLT3,GAK,INSR,IRAK1,IRAK3,IRAK4,LRRK2,MAP3K7,MAP4K1,MAP4K3,MAP4K5,NUAK1,PIK3CD,PTK2,SIK2,TEK | 23 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| July 5, 1967 | FDA | CNTY LINE PHARMS |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Urinary tract infection | 143.03 | 21.56 | 101 | 2895 | 305531 | 90319920 |
| Endocarditis enterococcal | 74.98 | 21.56 | 12 | 2984 | 247 | 90625204 |
| Respiratory syncytial virus test positive | 69.96 | 21.56 | 14 | 2982 | 1044 | 90624407 |
| Mitral valve replacement | 66.74 | 21.56 | 12 | 2984 | 503 | 90624948 |
| Aortic valve replacement | 53.51 | 21.56 | 11 | 2985 | 938 | 90624513 |
| Fall | 39.93 | 21.56 | 63 | 2933 | 481747 | 90143704 |
| Drug monitoring procedure not performed | 26.68 | 21.56 | 6 | 2990 | 781 | 90624670 |
| Hyperammonaemia | 24.88 | 21.56 | 9 | 2987 | 6466 | 90618985 |
| Cystitis | 24.17 | 21.56 | 19 | 2977 | 66699 | 90558752 |
| Emotional distress | 23.98 | 21.56 | 15 | 2981 | 36647 | 90588804 |
| Hypothermia | 23.21 | 21.56 | 11 | 2985 | 15564 | 90609887 |
| Urine analysis abnormal | 22.87 | 21.56 | 8 | 2988 | 5213 | 90620238 |
| Thyroid cancer metastatic | 22.78 | 21.56 | 4 | 2992 | 146 | 90625305 |
FDA Adverse Event Reporting System (Male)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Urinary tract infection | 64.04 | 37.08 | 32 | 703 | 99252 | 42521348 |
| Pathogen resistance | 37.58 | 37.08 | 12 | 723 | 11438 | 42609162 |
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Urinary tract infection | 135.59 | 20.84 | 96 | 3166 | 326186 | 110259851 |
| Endocarditis enterococcal | 71.84 | 20.84 | 12 | 3250 | 365 | 110585672 |
| Respiratory syncytial virus test positive | 66.73 | 20.84 | 14 | 3248 | 1480 | 110584557 |
| Mitral valve replacement | 65.76 | 20.84 | 12 | 3250 | 614 | 110585423 |
| Aortic valve replacement | 48.85 | 20.84 | 11 | 3251 | 1615 | 110584422 |
| Fall | 41.33 | 20.84 | 68 | 3194 | 603414 | 109982623 |
| Drug monitoring procedure not performed | 24.23 | 20.84 | 6 | 3256 | 1324 | 110584713 |
| Pathogen resistance | 23.08 | 20.84 | 11 | 3251 | 17661 | 110568376 |
| Thyroid cancer metastatic | 22.44 | 20.84 | 4 | 3258 | 179 | 110585858 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | G04BX17 | GENITO URINARY SYSTEM AND SEX HORMONES UROLOGICALS UROLOGICALS Other urologicals |
| ATC | J01XX05 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER ANTIBACTERIALS Other antibacterials |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000892 | Anti-Infective Agents, Urinary |
| MeSH PA | D000900 | Anti-Bacterial Agents |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| CHEBI has role | CHEBI:35441 | antiinfective agent |
Related Drugs by ATC class:
G04BX Other urologicals 10 drugs
J01XX Other antibacterials 12 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Urinary tract infectious disease | indication | 68566005 | |
| Prevention of Bacterial Urinary Tract Infection | indication | ||
| Gastritis | contraindication | 4556007 | DOID:4029 |
| Hypocalcemia | contraindication | 5291005 | |
| Severe chronic ulcerative colitis | contraindication | 14311001 | |
| Disorder of autonomic nervous system | contraindication | 15241006 | |
| Cirrhosis of liver | contraindication | 19943007 | DOID:5082 |
| Hyperphosphatemia | contraindication | 20165001 | DOID:0050459 |
| Glaucoma | contraindication | 23986001 | DOID:1686 |
| Toxic megacolon | contraindication | 28536002 | DOID:1770 |
| Atony of colon | contraindication | 29479008 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Glomerulonephritis | contraindication | 36171008 | DOID:2921 |
| Acute hepatitis | contraindication | 37871000 | |
| Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
| Hypernatremia | contraindication | 39355002 | |
| Hypovolemic shock | contraindication | 39419009 | |
| Gastrointestinal ulcer | contraindication | 40845000 | |
| Body fluid retention | contraindication | 43498006 | |
| Uremia | contraindication | 44730006 | DOID:4676 |
| Conduction disorder of the heart | contraindication | 44808001 | |
| Achalasia of esophagus | contraindication | 45564002 | DOID:9164 |
| Chronic heart failure | contraindication | 48447003 | |
| Disorder of cardiovascular system | contraindication | 49601007 | DOID:1287 |
| Vitamin K deficiency | contraindication | 52675005 | DOID:11249 |
| Nasal polyp | contraindication | 52756005 | |
| Paralytic ileus | contraindication | 55525008 | DOID:8442 |
| Acute nephropathy | contraindication | 58574008 | |
| Hepatic failure | contraindication | 59927004 | |
| Blood coagulation disorder | contraindication | 64779008 | DOID:1247 |
| Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
| Factor II deficiency | contraindication | 73975000 | |
| Gastrointestinal hemorrhage | contraindication | 74474003 | |
| Thrombotic thrombocytopenic purpura | contraindication | 78129009 | DOID:10772 |
| Hiatal hernia | contraindication | 84089009 | DOID:12642 |
| Kidney disease | contraindication | 90708001 | DOID:557 |
| Thyrotoxicosis | contraindication | 90739004 | DOID:7997 |
| Hemophilia | contraindication | 90935002 | |
| Myasthenia gravis | contraindication | 91637004 | DOID:437 |
| Anemia due to enzyme deficiency | contraindication | 111577008 | |
| Deficiency of glucose-6-phosphate dehydrogenase | contraindication | 124134002 | DOID:2862 |
| Liver function tests abnormal | contraindication | 166603001 | |
| Gastroesophageal reflux disease | contraindication | 235595009 | DOID:8534 |
| Disease of liver | contraindication | 235856003 | DOID:409 |
| Bladder outflow obstruction | contraindication | 236645006 | |
| Pyloric obstruction | contraindication | 244815007 | |
| Benign prostatic hyperplasia | contraindication | 266569009 | |
| Edema | contraindication | 267038008 | |
| Anemia | contraindication | 271737000 | DOID:2355 |
| Pregnancy, function | contraindication | 289908002 | |
| Cardiovascular event risk | contraindication | 395112001 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Disorder of coronary artery | contraindication | 414024009 | |
| Fever greater than 100.4 Fahrenheit | contraindication | 426000000 | |
| Severe dehydration | contraindication | 450316000 |
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cats | Urinary tract infections | Indication |
| Cats | Management of complications resulting from surgical manipulations of the urinary tract | Indication |
| Dogs | Urinary tract infections | Indication |
| Dogs | Management of complications resulting from surgical manipulations of the urinary tract | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Mesulfin Tablets | Zoetis Inc. | 2 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.59 | Basic |
| pKa2 | 5.59 | Basic |
| pKa3 | 1.09 | Basic |
| pKa4 | 1.0 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| 4018578 | VUID |
| N0000146894 | NUI |
| D00393 | KEGG_DRUG |
| 5714-73-8 | SECONDARY_CAS_RN |
| 587-23-5 | SECONDARY_CAS_RN |
| 4017868 | VANDF |
| 4017869 | VANDF |
| 4018578 | VANDF |
| C0025638 | UMLSCUI |
| CHEBI:6824 | CHEBI |
| CHEMBL1201270 | ChEMBL_ID |
| DB06799 | DRUGBANK_ID |
| CHEMBL1201104 | ChEMBL_ID |
| CHEMBL3833312 | ChEMBL_ID |
| D008709 | MESH_DESCRIPTOR_UI |
| 4101 | PUBCHEM_CID |
| 119 | INN_ID |
| 10913 | IUPHAR_LIGAND_ID |
| C011481 | MESH_SUPPLEMENTAL_RECORD_UI |
| C023055 | MESH_SUPPLEMENTAL_RECORD_UI |
| J50OIX95QV | UNII |
| 161623 | RXNORM |
| 5069 | MMSL |
| 5070 | MMSL |
| 5071 | MMSL |
| 72179 | MMSL |
| 941 | MMSL |
| 945 | MMSL |
| d00106 | MMSL |
| 002861 | NDDF |
| 002862 | NDDF |
| 002863 | NDDF |
| 372773008 | SNOMEDCT_US |
| 55741006 | SNOMEDCT_US |
| 56123002 | SNOMEDCT_US |
| 68293009 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| URELLE | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0037-6321 | TABLET | 81 mg | ORAL | Unapproved drug other | 12 sections |
| URIBEL | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0076-0111 | CAPSULE | 120 mg | ORAL | unapproved drug other | 20 sections |
| Hyophen | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0076-0901 | TABLET | 81.60 mg | ORAL | unapproved drug other | 19 sections |
| Phosphasal | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0076-0902 | TABLET | 81.60 mg | ORAL | unapproved drug other | 20 sections |
| Ustell | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0076-0903 | CAPSULE | 120 mg | ORAL | unapproved drug other | 20 sections |
| Methenamine Hippurate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0115-1754 | TABLET | 1 g | ORAL | ANDA | 12 sections |
| URIBEL TABS | HUMAN PRESCRIPTION DRUG LABEL | 5 | 0178-0745 | TABLET, COATED | 81.60 mg | ORAL | unapproved drug other | 13 sections |
| Walgreens Pain Relief plus UTI Bacteria Control | HUMAN OTC DRUG LABEL | 2 | 0363-1277 | TABLET | 162 mg | ORAL | unapproved drug other | 10 sections |
| Walgreens Antibacterial Plus Urinary Pain Relief | HUMAN OTC DRUG LABEL | 2 | 0363-4404 | TABLET | 162 mg | ORAL | unapproved drug other | 10 sections |
| UROGESIC BLUE | HUMAN PRESCRIPTION DRUG LABEL | 4 | 0485-0151 | TABLET, COATED | 81.60 mg | ORAL | unapproved drug other | 18 sections |
| UROGESIC BLUE | HUMAN PRESCRIPTION DRUG LABEL | 4 | 0485-0151 | TABLET, COATED | 81.60 mg | ORAL | unapproved drug other | 18 sections |
| Preferred Antibacterial Plus Urinary Pain Relief | HUMAN OTC DRUG LABEL | 2 | 10956-763 | TABLET | 162 mg | ORAL | unapproved drug other | 10 sections |
| Rite Aid Antibacterial Plus Urinary Pain Relief | HUMAN OTC DRUG LABEL | 2 | 11822-4892 | TABLET | 162 mg | ORAL | unapproved drug other | 10 sections |
| Uretron D/S | HUMAN PRESCRIPTION DRUG LABEL | 5 | 12539-144 | TABLET | 81.60 mg | ORAL | unapproved drug other | 20 sections |
| UroAv-81 | HUMAN PRESCRIPTION DRUG LABEL | 5 | 15338-502 | TABLET | 81 mg | ORAL | unapproved drug other | 18 sections |
| UroAv-B | HUMAN PRESCRIPTION DRUG LABEL | 5 | 15338-503 | CAPSULE | 118 mg | ORAL | unapproved drug other | 18 sections |
| URIMAR-T CAPS | HUMAN PRESCRIPTION DRUG LABEL | 5 | 28595-224 | CAPSULE | 120 mg | ORAL | unapproved drug other | 19 sections |
| MB CAPS | HUMAN PRESCRIPTION DRUG LABEL | 5 | 28595-299 | CAPSULE | 120 mg | ORAL | unapproved drug other | 18 sections |
| HIPREX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 30698-477 | TABLET | 1 g | ORAL | NDA | 13 sections |
| TopCare Antibacterial Plus Urinary Pain Relief | HUMAN OTC DRUG LABEL | 2 | 36800-314 | TABLET | 162 mg | ORAL | unapproved drug other | 10 sections |
| Meijer Antibacterial Plus Urinary Pain Relief | HUMAN OTC DRUG LABEL | 2 | 41250-557 | TABLET | 162 mg | ORAL | unapproved drug other | 10 sections |
| Methenamine Hippurate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42571-332 | TABLET | 1000 mg | ORAL | ANDA | 11 sections |
| Methenamine Mandelate | Human Prescription Drug Label | 1 | 42799-105 | TABLET | 500 mg | ORAL | UNAPPROVED DRUG OTHER | 13 sections |
| Methenamine Mandelate | Human Prescription Drug Label | 1 | 42799-106 | TABLET | 1000 mg | ORAL | UNAPPROVED DRUG OTHER | 13 sections |
| Good Neighbor Antibacterial Plus Urinary Pain Relief | HUMAN OTC DRUG LABEL | 2 | 46122-622 | TABLET | 162 mg | ORAL | unapproved drug other | 10 sections |
| Methenamine Hippurate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 47781-577 | TABLET | 1 g | ORAL | NDA | 22 sections |
| Azo Urinary Tract DefenseAntibacterial Protection | HUMAN OTC DRUG LABEL | 2 | 49973-011 | TABLET | 162 mg | ORAL | unapproved drug other | 16 sections |
| Methenamine Hippurate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50268-549 | TABLET | 1000 mg | ORAL | ANDA | 11 sections |
| METHENAMINE HIPPURATE | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50742-142 | TABLET | 1 g | ORAL | ANDA | 14 sections |
| CVS DUAL ACTION PAIN RELIEF | HUMAN OTC DRUG LABEL | 2 | 51316-777 | TABLET | 162 mg | ORAL | unapproved drug other | 10 sections |